| Gene Symbol | CD47 |
| Full Name | SIRPα Immune Checkpoint Therapy |
| Function | CD47 is a transmembrane protein that acts as a "don't eat me" signal by binding to SIRPα on macrophages and other phagocytic cells. |
| Primary Expression | various brain regions and cell types, where it contributes to cellular signaling, gene regulation, and homeostasis |
| Amino Acids | 323 aa |
| Pathways | Adaptive Immunity, Amyloid, Apoptosis, Complement, Endocytosis |
| Ensembl ID | ENSG00000196776 |
| GeneCards | CD47 |
| Human Protein Atlas | CD47 |
| Combination | Rationale |
| NLRP3 inhibitor + Anti-CD47 | Reduce inflammation (NLRP3) + enhance clearance (CD47) |
| TREM2 agonist + Anti-CD47 | Activate phagocytosis via two complementary pathways |
| Anti-CD47 + ASO therapy | Enhance aggregate clearance while reducing production |
| Drug | Company |
| Magrolimab | Gilead |
| Associated Diseases | ALS, Aging, Alzheimer, Cancer, Glioblastoma |
| Interactions | GFAP, MMP9, TNF, TLR4, CD68, MMP2 |
| KG Connections | 387 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |